LA FDA HA LEVANTADO LA SUSPENSIÓN CLÍNICA DEL ADC MÁS PROMETEDOR COMO POSIBLE TRATAMIENTO SMALL CELL LUNG CANCER TANTO PARA PRIMERA LÍNEA , MANTENIMIENTO , SEGUNDA LÍNEA ... POR LO QUE IFINATAMAB DERUXTECAN DE MERCK Y DAIICHI CONTINUA CON PASO FIRME Y ACELERADO HACIA SU MÁS QUE PROBABLE APROBACIÓN Y PODER APORTAR A LOS PACIENTES VIDA Y ESPERANZA DONDE EL RESTO DE TRATAMIENTOS NO LLEGAN .
26 enero 2009
Pfizer could pay $68 billion for Wyeth .
An agreement between the drug makers might be announced Monday. It would be the largest acquisition in five years for the industry.
Bloomberg
January 26, 2009
New York -- Pfizer Inc. would pay about $68 billion to acquire Wyeth in a bid reviewed Sunday by boards for the two drug companies, according to people familiar with the talks.
Bloomberg
January 26, 2009
New York -- Pfizer Inc. would pay about $68 billion to acquire Wyeth in a bid reviewed Sunday by boards for the two drug companies, according to people familiar with the talks.
Suscribirse a:
Comentarios (Atom)